William John Scheessele - Dec 8, 2023 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Chief Commercial Officer
Signature
/s/ William John Scheessele by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
Dec 8, 2023
Transactions value $
$0
Form type
4
Date filed
12/12/2023, 04:10 PM
Previous filing
Dec 15, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +276K $0.00 276K Dec 8, 2023 Common Stock 276K $2.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.